ATLAS-M 研究:阿扎那韦/利托那韦+拉米夫定简化治疗 48 周结果
ATLAS-M 是一项开放标签、多中心、随机、非劣效性研究,纳入病毒学抑制的 HIV-1 感染成人,比较简化为阿扎那韦/利托那韦+拉米夫定与维持阿扎那韦/利托那韦+两种 NRTI 的 48 周疗效。结果显示简化组达到主要结局的比例为 89.5%,维持组为 79.7%,差异 +9.8%(95% CI +1.2 至 +18.4),证明非劣效且事后分析显示优效,安全性与维持组相当。
要点
- 病毒学抑制患者简化为阿扎那韦/利托那韦+拉米夫定 48 周非劣效于三药方案。
- 简化组主要结局 89.5%,维持组 79.7%,差异 +9.8%(95% CI +1.2 至 +18.4)。
- 两组不良事件发生率相似,病毒学失败少见且无耐药选择。
核心结论
- 简化为阿扎那韦/利托那韦+拉米夫定在病毒学抑制患者中显示非劣效疗效(事后分析显示优效),安全性与继续三药方案相当。
研究设计与样本
- 开放标签、多中心、随机、非劣效性研究,纳入 266 例接受阿扎那韦/利托那韦+两种 NRTI 且 HIV-RNA <50 copies/mL、CD4+ >200 cells/mm3 的 HIV 感染成人,1:1 随机分组。
主要发现
- 48 周主要结局(ITT-e 分析,switch=failure)在简化组为 119/133(89.5%),维持组为 106/133(79.7%),差异 +9.8%(95% CI +1.2 至 +18.4)。
- 病毒学失败在简化组发生 2 例(1.5%),维持组 6 例(4.5%),均无耐药选择。
- 两组不良事件发生比例相似。
关键数值与推荐
- 非劣效性界值为 12%。
- 主要结局为第 48 周维持 HIV-RNA <50 copies/mL。
临床怎么用
- 对于已稳定抑制且无乙肝合并感染、无研究药物失败史或耐药、无近期 AIDS 及妊娠的 HIV 感染者,可考虑简化为阿扎那韦/利托那韦+拉米夫定。
局限性
- 开放标签设计;排除乙肝病毒合并感染、研究药物既往失败或耐药、近期 AIDS 及妊娠患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Combination ART (cART)-related toxicities and costs have prompted the need for treatment simplification. The ATLAS-M trial explored 48 week non-inferior efficacy of simplification to atazanavir/ritonavir + lamivudine versus maintaining three-drug atazanavir/ritonavir-based cART in virologically suppressed patients. METHODS: We performed an open-label, multicentre, randomized, non-inferiority study, enrolling HIV-infected adults on atazanavir/ritonavir + two NRTIs, with stable HIV-RNA <50 copies/mL and CD4 + >200 cells/mm 3 . Main exclusion criteria were hepatitis B virus coinfection, past virological failure on or resistance to study drugs, recent AIDS and pregnancy. Patients were randomly assigned 1:1 to either switch to 300 mg of atazanavir/100 mg of ritonavir once daily and 300 mg of lamivudine once daily (atazanavir/ritonavir + lamivudine arm) or to continue the previous regimen (atazanavir/ritonavir + two NRTIs arm). The primary study outcome was the maintenance of HIV-RNA <50 copies/mL at week 48 of the ITT-exposed (ITT-e) analysis with switch = failure. The non-inferiority margin was 12%. This study is registered at ClinicalTrials.gov, number NCT01599364. RESULTS: Between July 2011 and June 2014, 266 patients were randomized (133 to each arm). After 48 weeks, the primary study outcome was met by 119 of 133 patients (89.5%) in the atazanavir/ritonavir + lamivudine arm and 106 of 133 patients (79.7%) in the atazanavir/ritonavir + two NRTIs arm [difference atazanavir/ritonavir + lamivudine versus atazanavir/ritonavir + two NRTIs arm: +9.8% (95% CI + 1.2 to + 18.4)], demonstrating non-inferiority and superior efficacy of the atazanavir/ritonavir + lamivudine arm. Virological failure occurred in two (1.5%) patients in the atazanavir/ritonavir + lamivudine arm and six (4.5%) patients in the atazanavir/ritonavir + two NRTIs arm, without resistance selection. A similar proportion of adverse events occurred in both arms. CONCLUSIONS: Treatment simplification to atazanavir/ritonavir + lamivudine showed non-inferior efficacy (superiority on post-hoc analysis) and a comparable safety profile over continuing atazanavir/ritonavir + two NRTIs in virologically suppressed patients.
引用
- Di Giambenedetto S, Fabbiani M, Quiros Roldan E, et al. Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). J Antimicrob Chemother. 2017. PMID: 28093483. doi:10.1093/jac/dkw557
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。